Cadence Pharmaceuticals Company Description
Cadence Pharmaceuticals follows the rhythm of hospitals' medical needs. The biopharmaceutical company develops drug candidates primarily for use in a hospital setting. The company licenses rights to compounds and develops them for sale in untapped markets or for new indications. Cadence's late-stage candidates include Acetavance (injectable acetaminophen), which is marketed in Europe by the Bristol-Myers Squibb Company under the name Perfalgan, for treating acute pain and fever. The company also is developing Omigard, a topical antimicrobial gel used to prevent and treat infections in surgical wounds, burns, and medical device-related wounds such as from catheters.
View the Comprehensive Company Description for Cadence Pharmaceuticals
The Company Description provides a historical perspective of Cadence Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Cadence Pharmaceuticals's evolution in the marketplace.
